After finishing at $1.45 in the prior trading day, Bluebird bio Inc (NASDAQ: BLUE) closed at $1.50, up 3.45%. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 9420727 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of BLUE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Obenshain Andrew sold 6,095 shares for $1.53 per share. The transaction valued at 9,311 led to the insider holds 279,998 shares of the business.
Klima Thomas J sold 4,573 shares of BLUE for $6,986 on Mar 04 ’24. The insider now owns 124,840 shares after completing the transaction at $1.53 per share. On Mar 01 ’24, another insider, Colvin Richard A, who serves as the Chief Medical Officer of the company, sold 6,770 shares for $1.53 each. As a result, the insider received 10,342 and left with 118,368 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 289.11M and an Enterprise Value of 418.53M. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.30 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at 19.26 whereas that against EBITDA is -3.18.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is 1.2640, while the 200-Day Moving Average is calculated to be 2.8405.
Shares Statistics:
The stock has traded on average 14.52M shares per day over the past 3-months and 14.07M shares per day over the last 10 days, according to various share statistics. A total of 192.74M shares are outstanding, with a floating share count of 189.80M. Insiders hold about 1.53% of the company’s shares, while institutions hold 67.23% stake in the company. Shares short for BLUE as of Feb 15, 2024 were 28.59M with a Short Ratio of 1.97, compared to 26.57M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.83% and a Short% of Float of 15.84%.
Earnings Estimates
Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$0.98, while EPS last year was $0.38. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.24 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1 and -$2.26 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.77, with 13 analysts recommending between -$0.95 and -$3.09.
Revenue Estimates
10 analysts predict $16.62M in revenue for the current quarter. It ranges from a high estimate of $21.5M to a low estimate of $11.51M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62k, an estimated increase of 26,706.50% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $20.12M, an increase of 745.00% less than the figure of $26,706.50% in the same quarter last year. There is a high estimate of $29.2M for the next quarter, whereas the lowest estimate is $12.2M.
A total of 13 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $49M, while the lowest revenue estimate was $33.18M, resulting in an average revenue estimate of $40.56M. In the same quarter a year ago, actual revenue was $3.6M, up 1,027.60% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $125.77M in the next fiscal year. The high estimate is $173M and the low estimate is $56.72M. The average revenue growth estimate for next year is up 210.10% from the average revenue estimate for this year.
